These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
133 related items for PubMed ID: 37125735
21. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors. Ono R, Nishimura K, Takahashi H, Hori Y, Fukushima K, Kobayashi Y. Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895 [Abstract] [Full Text] [Related]
22. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator. Billoir P, Barbay V, Joly LM, Fresel M, Chrétien MH, Le Cam Duchez V. Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443 [Abstract] [Full Text] [Related]
24. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Schellings MW, Boonen K, Schmitz EM, Jonkers F, van den Heuvel DJ, Besselaar A, Hendriks JG, van de Kerkhof D. Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310 [Abstract] [Full Text] [Related]
28. The PiCT® test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study. Brisset AC, Ferrández A, Krause M, Rathbun S, Marlar R, Korte W. J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411 [Abstract] [Full Text] [Related]
29. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution. Park SH, Seo YH, Park PW, Kim KH, Seo JY, Lee HT, Kwoun WJ, Ahn JY. J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622 [Abstract] [Full Text] [Related]
30. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Crit Care; 2017 Feb 15; 21(1):32. PubMed ID: 28196509 [Abstract] [Full Text] [Related]
31. Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS. Liu H, Zhao Z, Wang Y, Liu L, Yang Y, An Z. Curr Drug Metab; 2021 Feb 15; 22(14):1132-1138. PubMed ID: 34825867 [Abstract] [Full Text] [Related]
37. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level? Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Ann Pharmacother; 2015 Jul 15; 49(7):777-83. PubMed ID: 25855705 [Abstract] [Full Text] [Related]
39. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Gosselin RC, Adcock D, Hawes EM, Francart SJ, Grant RP, Moll S. Thromb Haemost; 2015 Jan 15; 113(1):77-84. PubMed ID: 25413383 [Abstract] [Full Text] [Related]